This state-of-the-art review provides a description of the device-related thrombotic risk associated with transcatheter structural heart interventions and of the current evidence-based guidelines regarding antithrombotic treatments. Gaps in evidence for each of the studied transcatheter interventions and the main ongoing trials are also summarised. https://t.co/b4Kx4DAyDP
From #EHJIMP, new interesting review: "Combining cardiopulmonary exercise testing with echocardiography: a multiparametric approach to the cardiovascular and cardiopulmonary systems"
https://t.co/nyPCrUs5XN
@escardio@ESC_Journals@alessia_gimelli#echofirst#CPET
The visual summaries of all Hot Line trials at #ESCCongress 2023 are an extremely useful resource provided by @escardio.
Free access at https://t.co/kF9CVZVRyS
#CardioTwitter
Compared to ACEI+BB, treatment with disease-modifying quadruple ARNI+BB+MRA+SGLTi in eligible patients with HFrEF
➡️ additional years of overall survival
55 yo: 6.3 years
65 yo: 4.4 years
70 yo: 3.9 years
75 yo: 3.1 years
80 yo: 1.4 years
Not days, weeks, or months…
Years!
This article proposes a standardised approach to evaluate patients with TR who may be candidates for transcatheter interventions. Read more on the available transcatheter therapies, the main criteria for patient and device selection. #EIJBestOf@FabienPraz https://t.co/dGTO1gWjjD
In patients with structural heart disease, the basal septum is a common source of ventricular #tachycardia (VT).
Read this elegant review of both the clinical and electrophysiological characteristics of VT from this area: https://t.co/BA9uW3oaDC
#JACCCEP#HeartDisease#EPeeps